Each Friday, we provide an update on the current live tracking portfolio (as of the previous day’s closing prices), a summary of the last week of trading activity, and updates on any significant developments among the companies we have positions in.
In this week’s issue of The Big Secret On Wall Street, we perform a brief market analysis and a comprehensive portfolio review on six of our holdings as well as offering actions to take.
The company we are recommending presents such a favorable risk/reward today because we can purchase the stock at a significant discount to the value of its legacy business alone – ignoring the hidden blockchain asset on its balance sheet altogether.
In this week’s issue of The Big Secret On Wall Street, we provide excerpts from recommendations of the three top-performing Best Buys – each company held a position in our Best Buys feature for an extended period, generating returns that outperformed the rest of the portfolio and the overall market, represented by the S&P 500.
In this week’s issue of The Big Secret On Wall Street, we perform a comprehensive portfolio review. Given our focus on long-term investments, the three-year mark has provided an adequate track record to officially see how we are doing.
Burford Capital is the world’s largest provider of litigation finance – offering the capital and legal expertise that enable its clients to pursue litigation they might not otherwise be able to pursue. In this report, we explain why a recent legal victory could unleash a windfall of $3 billion, equal to the entire market capitalization of the company.
When used correctly, selling puts is an incredibly powerful strategy that gives everyday investors the chance to generate income, reinvest in other opportunities, or to purchase equities at below-market prices. But if used indiscriminately, this strategy can easily wipe out a portfolio. Today, we discuss how to do it the right way.
Sable Offshore was first recommended on December 20, 2024. Now, it looks even better: the risk has diminished and shares have much a higher floor with even greater upside than we estimated five months ago.
Dear Biotech Frontiers subscribers, One of the most important qualities that separates professional investors from amateurs is the capacity to face reality when it becomes clear an investment thesis has broken down. As I’ve said before, hope is not a strategy. Unfortunately, that moment has come regarding our Biotech Frontiers investment in Iovance Biotherapeutics (Nasdaq:
We look at how the portfolio of six stocks we expected to benefit from the second Trump administration has performed following the U.S. president’s first 100 days in office.